GSK
NEUTRALGSK Announces Director/PDMR Shareholding Changes
The healthcare company has announced changes to the shareholdings of a senior executive and a person closely associated with them.
GSK
1,397.50GBX
0.54%
Market Cap
56.54B
Volume
4.64M
45% of avg
P/E Ratio
8.32
EPS (TTM)
1.68
Beta
0.27
Day Range
1,383.86p - 1,408.00p
52 Week Range
1,242.50p1,397.50p1,678.68p
1,397.50p
Upcoming Events
GSK
NEUTRALGSK Announces Non-Executive Director Appointment
The healthcare company announces a change in its board of directors, with a non-executive director taking on a new role at another company.
GSK
NEUTRALGSK Announces Director/PDMR Shareholding
The healthcare company has disclosed changes to director and PDMR shareholdings.
GSK
NEUTRALGSK Announces Director/PDMR Shareholding
The pharmaceutical company has announced share purchases by several non-executive directors.
GSK
NEUTRALGSK Announces Linerixibat Accepted for Review by EMA for Cholestatic Pruritus in PBC
The pharmaceutical company announced that its investigational drug linerixibat has been accepted for review by the European Medicines Agency for the treatment of a rare liver disease condition.
GSK
NEUTRALGSK Submits Arexvy for adults 18+ with EMA
The healthcare company has submitted a new drug for regulatory review in Europe, marking a step forward in its pipeline development.
GSK
NEUTRALGSK's RSV vaccine Arexvy filed for expanded use in Japan
The healthcare company has filed for regulatory approval to expand the use of its RSV vaccine in Japan to include adults aged 18-49 at increased risk.
GSK
NEUTRALGSK Director Sells Shares
The major pharmaceutical company announced a director has sold a portion of their shareholding.
GSK
NEUTRALGSK Seeks Expanded Use of RSV Vaccine Arexvy in Adults
The healthcare company has submitted its RSV vaccine for regulatory review to expand use to adults 18 and older.
GSK
NEUTRALGSK Announces Director Share Sale
The major pharmaceutical company has announced a sale of shares by a senior executive.